SOURCE: AtheroNova Inc.

AtheroNova Inc.

December 22, 2010 08:45 ET

AtheroNova Addresses Study Indicating Millions of Patients With Obstructive Sleep Apnea Prone to Aggressive Atherosclerosis

IRVINE, CA--(Marketwire - December 22, 2010) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, commented on a study presented at the annual meeting of the Radiological Society of North America (RSNA) using CT angiography indicating that obese patients with Obstructive Sleep Apnea (OSA) were prone to an aggressive form of atherosclerosis characterized by increased amounts of soft plaque deposits in coronary arteries.

"The research presented at the recent RSNA meeting indicating a very high coronary artery soft vulnerable plaque burden in OSA patients is an important finding and reflects innovative analyses on the part of the researchers," stated Thomas W. Gardner, CEO of AtheroNova. "The researchers used CT angiography (cCTA) as a non-invasive screening method to evaluate the coronary artery plaque burden for the presence of dangerous soft vulnerable plaque and suggested that cCTA could become a screening tool for obese individuals at increased risk for cardiovascular disease."

"In light of the results of our initial animal study that demonstrated a 95% less occurrence of arterial plaque compared to the control group, the RSNA OSA findings present an important opportunity to identify specific patient populations with an aggressive form of atherosclerosis that may be particularly well suited for treatment with our compounds. As we commence our second round of pre-clinical studies and prepare for an Investigative New Drug application and the commencement of Phase I human trials, the possibility of using a non-invasive screening technology to not only identify a large patient population with dangerous soft vulnerable plaque burden, but to also quantify and assess a reduction or regression in plaque burden during and following treatment, may pave the way for ongoing development of applications for our compounds. We have an ongoing interest in developing clinical trials to study the safety and efficacy of our plaque regression intellectual property," concluded Mr. Gardner.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the preclinical trials being conducted by the Company, the expected time to completion of the research, and the suitability of its compounds for certain applications. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company contact:

    Thomas Gardner
    Chief Executive Officer
    (949) 476-1100

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:

    Leon Hamerling
    Investor Media Group
    (877) 725-2500